StockData
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc. (TYRA) stock

TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$19.57−0.17 (-0.86%)

Close on Nov 17, 2026Market cap $1.17BP/E –Yield –

Tyra Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Tyra Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$109.65M. For fiscal 2025 it was -$95.14M. The highest annual figure on record is -$7.76M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$95.14M–
FY2024Dec 31, 2024-$69.77M–
FY2023Dec 31, 2023-$50.14M–
FY2022Dec 31, 2022-$50.29M–
FY2021Dec 31, 2021-$23.75M–
FY2020Dec 31, 2020-$7.76M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$31.08M–
Q1 FY2026Mar 31, 2026-$32.57M–
Q4 FY2025Dec 31, 2025-$23.62M–
Q3 FY2025Sep 30, 2025-$22.38M–
Q2 FY2025Jun 30, 2025-$23.68M–
Q1 FY2025Mar 31, 2025-$25.46M–
Q4 FY2024Dec 31, 2024-$19.59M–
Q3 FY2024Sep 30, 2024-$17.90M–
Q2 FY2024Jun 30, 2024-$10.26M–
Q1 FY2024Mar 31, 2024-$22.03M–
Q4 FY2023Dec 31, 2023-$13.53M–
Q3 FY2023Sep 30, 2023-$17.15M–
Q2 FY2023Jun 30, 2023-$9.62M–
Q1 FY2023Mar 31, 2023-$9.85M–
Q4 FY2022Dec 31, 2022-$11.98M–
Q3 FY2022Sep 30, 2022-$12.21M–
Q2 FY2022Jun 30, 2022-$17.17M–
Q1 FY2022Mar 31, 2022-$8.93M–
Q4 FY2021Dec 31, 2021-$9.03M–
Q3 FY2021Sep 30, 2021-$5.58M–
Q2 FY2021Jun 30, 2021-$4.46M–
Q1 FY2021Mar 31, 2021-$4.68M–
Q4 FY2020Dec 31, 2020-$2.53M–

More Tyra Biosciences figures

See a number that looks wrong?